The US Food and Drug Administration (FDA) has granted Fast Track Designation to a first-in-class vectorised antibody for the treatment of amyotrophic lateral sclerosis (ALS). 

VTx-002, developed by biotechnology company VectorY Therapeutics, targets TDP-43 pathology, which drives up to 97% of ALS cases. 

Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions, filling an unmet medical need. A therapy that receives Fast Track designation may be eligible for more frequent meetings and communications with the FDA and may also be eligible for Priority Review in the future. 

“ALS is a devastating and relentlessly progressive disease with profound unmet medical need, and patients urgently need new therapeutic options,” said Jim Scibetta, Chief Executive Officer of VectorY.  

“The FDA’s decision to grant Fast Track designation to VTx-002 underscores the seriousness of ALS and the importance of advancing new investigational approaches.  

“This designation enables closer and more frequent interaction with the FDA as we prepare to advance VTx-002 into the upcoming PIONEER-ALS Phase I/II clinical study, with the goal of moving as efficiently and responsibly as possible on behalf of patients.” 

VectorY plans to enrol its first patient in the PIONEER-ALS study in early 2026. 

Bruno Quinney, Content Team, DDW